Literature DB >> 7321548

Fluorescence polarization immunoassay for the determination of therapeutic drug levels in human plasma.

M E Jolley.   

Abstract

Fluorescence polarization immunoassay (FPIA) is a technique which has been known for a number of years, but despite its many advantages, its has not seen clinical utility. The main reason for this is the lack of simple, rapid, high performance instrumentation suitable for use in a clinical laboratory. This problem has been addressed in this laboratory and an instrument has been developed which meets these needs. The solutions of the two other problems associated with the technique (i.e. non-specific binding of tracer to serum proteins and the intrinsic fluorescence of serum) have also been accomplished. Assays for a variety of therapeutic drugs including gentamicin, theophylline, phenytoin, and phenobarbital have been developed and shown to correlate well with a number of reference method. The assays have been totally automated with a concomitant increase in speed and ease of use and a significant improvement in performance over the manual system.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7321548     DOI: 10.1093/jat/5.5.236

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  24 in total

1.  The screening for common drugs of abuse in whole blood by means of EMIT-ETS and FPIA-ADx urine immunoassays.

Authors:  R D Maier; M Erkens; H Hoenen; M Bogusz
Journal:  Int J Legal Med       Date:  1992       Impact factor: 2.686

Review 2.  Fluorescence polarization/anisotropy in diagnostics and imaging.

Authors:  David M Jameson; Justin A Ross
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

3.  Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs.

Authors:  Soo-Han Lee; Hyun-Ji Kang; Seok-Joon Jin; Do-Yang Park; Yoon-Ji Choi; Byung-Moon Choi; Eun-Kyung Lee; Gyu-Jeong Noh
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-24       Impact factor: 2.745

4.  Serum bactericidal activity and killing rate for volunteers receiving imipenem, imipenem plus amikacin, and ceftazidime plus amikacin against Pseudomonas aeruginosa.

Authors:  P Van der Auwera; J Klastersky; H Lagast; M Husson
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

5.  Modification of the Mycobacterium bovis extracellular protein MPB70 with fluorescein for rapid detection of specific serum antibodies by fluorescence polarization.

Authors:  M Lin; E A Sugden; M E Jolley; K Stilwell
Journal:  Clin Diagn Lab Immunol       Date:  1996-07

6.  Use of recombinant flagellin protein as a tracer antigen in a fluorescence polarization assay for diagnosis of leptospirosis.

Authors:  N I Bughio; M Lin; O P Surujballi
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

7.  Two-dimensional fluorescence intensity distribution analysis: theory and applications.

Authors:  P Kask; K Palo; N Fay; L Brand; U Mets; D Ullmann; J Jungmann; J Pschorr; K Gall
Journal:  Biophys J       Date:  2000-04       Impact factor: 4.033

8.  Bactericidal activity and killing rate of serum from volunteers receiving pefloxacin alone or in combination with amikacin.

Authors:  P Van der Auwera; J Klastersky; S Lieppe; M Husson; D Lauzon; A P Lopez
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

9.  Lorazepam and diazepam effects on memory acquisition in priming tasks.

Authors:  P Vidailhet; J M Danion; F Kauffmann-Muller; D Grangé; A Giersch; M van der Linden; J L Imbs
Journal:  Psychopharmacology (Berl)       Date:  1994-07       Impact factor: 4.530

10.  Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium.

Authors:  F Caron; M D Kitzis; L Gutmann; A C Cremieux; B Maziere; J M Vallois; A Saleh-Mghir; J F Lemeland; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.